ATE382364T1 - Von igf-bindungsprotein stammendes peptid - Google Patents

Von igf-bindungsprotein stammendes peptid

Info

Publication number
ATE382364T1
ATE382364T1 AT02759330T AT02759330T ATE382364T1 AT E382364 T1 ATE382364 T1 AT E382364T1 AT 02759330 T AT02759330 T AT 02759330T AT 02759330 T AT02759330 T AT 02759330T AT E382364 T1 ATE382364 T1 AT E382364T1
Authority
AT
Austria
Prior art keywords
binding protein
peptide derived
igf binding
disease
new
Prior art date
Application number
AT02759330T
Other languages
English (en)
Inventor
Desmond Mascarenhas
Original Assignee
Bioexpertise Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioexpertise Llc filed Critical Bioexpertise Llc
Application granted granted Critical
Publication of ATE382364T1 publication Critical patent/ATE382364T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02759330T 2001-09-18 2002-08-09 Von igf-bindungsprotein stammendes peptid ATE382364T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32326701P 2001-09-18 2001-09-18

Publications (1)

Publication Number Publication Date
ATE382364T1 true ATE382364T1 (de) 2008-01-15

Family

ID=23258422

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02759330T ATE382364T1 (de) 2001-09-18 2002-08-09 Von igf-bindungsprotein stammendes peptid

Country Status (8)

Country Link
US (1) US6861406B2 (de)
EP (1) EP1435986B1 (de)
JP (1) JP4344242B2 (de)
AT (1) ATE382364T1 (de)
AU (1) AU2002324672B2 (de)
CA (1) CA2460719A1 (de)
DE (1) DE60224419D1 (de)
WO (1) WO2003025121A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8070796B2 (en) * 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US7967855B2 (en) * 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US6914049B2 (en) * 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
AU2005243741B2 (en) * 2001-09-18 2010-01-28 Bioexpertise Llc Methods for delivering MBD peptide- linked agent into cells under conditions of cellular stress
US8740973B2 (en) * 2001-10-26 2014-06-03 Icon Medical Corp. Polymer biodegradable medical device
EP1670822A2 (de) * 2003-10-03 2006-06-21 Genentech, Inc. Igf-bindende proteine
WO2006017824A2 (en) * 2004-08-06 2006-02-16 The Trustees Of Columbia University In The City Of New York Igf-bp3-related methods for inhibiting tumor growth
US9339403B2 (en) * 2004-11-12 2016-05-17 Icon Medical Corp. Medical adhesive for medical devices
US7455688B2 (en) * 2004-11-12 2008-11-25 Con Interventional Systems, Inc. Ostial stent
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
WO2006096251A2 (en) * 2005-03-03 2006-09-14 Icon Medical Corp. Improved metal alloys for medical device
US20060200048A1 (en) * 2005-03-03 2006-09-07 Icon Medical Corp. Removable sheath for device protection
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
WO2006110197A2 (en) 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
US20060198869A1 (en) * 2005-03-03 2006-09-07 Icon Medical Corp. Bioabsorable medical devices
CA2629113A1 (en) * 2005-11-09 2007-05-18 Ontherix, Inc. Metal-binding therapeutic peptides
US20080039393A1 (en) * 2005-11-09 2008-02-14 Desmond Mascarenhas Metal-binding therapeutic peptides
US7611893B2 (en) 2005-11-09 2009-11-03 Ontherix, Inc. Metal-binding therapeutic peptides
US7662624B2 (en) * 2005-11-09 2010-02-16 Ontherix, Inc. Metal-binding therapeutic peptides
WO2008008291A2 (en) * 2006-07-13 2008-01-17 Icon Medical Corp. Stent
WO2008086813A2 (en) * 2007-01-19 2008-07-24 Kobenhavns Universitet Peptides derived from proteins of the insulin super-family
US8536135B2 (en) * 2008-03-19 2013-09-17 Ontherix, Inc. Adaptive biochemical signatures
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
US11266767B2 (en) 2014-06-24 2022-03-08 Mirus Llc Metal alloys for medical devices
WO2017026505A1 (ja) * 2015-08-11 2017-02-16 池田食研株式会社 結合剤
WO2017151548A1 (en) 2016-03-04 2017-09-08 Mirus Llc Stent device for spinal fusion
CN109071647B (zh) * 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US5200509A (en) 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
EP0597033B1 (de) 1991-08-01 1997-04-09 Genentech, Inc. IGF-I zur Verbesserung der neuronale Lage
US5407913A (en) 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
US5643867A (en) 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
AU674449B2 (en) 1993-08-03 1996-12-19 Celtrix Pharmaceuticals, Inc. Method of treating reproductive disorders
CA2172158A1 (en) 1993-09-20 1995-03-30 Joseph A. Carlino Treatment of immunologic and hematologic disorders with igfbp alone or complexed with igf
CA2176709A1 (en) 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
AU693489B2 (en) 1993-11-15 1998-07-02 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
US5861273A (en) 1993-12-21 1999-01-19 Celtrix Phamraceuticals, Inc. Chromosomal expression of heterologous genes in bacterial cells
AUPM672594A0 (en) 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
CA2195474A1 (en) 1994-07-20 1996-02-01 Cedo Martin Bagi Igf/igfbp complex for promoting bone formation and for regulating bone remodeling
AU718451B2 (en) 1995-09-14 2000-04-13 Bristol-Myers Squibb Company Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
DE19757250A1 (de) * 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
WO2000023469A2 (en) * 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
EP1290162A4 (de) 2000-05-17 2005-08-17 Univ Oregon Health Sciences Induktion von apoptose und hemmung des zellwachstums durch das 4.33 protein
WO2002024216A2 (en) * 2000-09-19 2002-03-28 Bioexpertise, Llc Method for use of igf-binding protein for selective sensitization of target cells in vivo
US7232880B2 (en) 2000-10-27 2007-06-19 Oregon Health & Science University Mutant IGFBP-3 molecules that do not bind to IGFS, but retain their ability to functionally bind IGFBP-3 receptor
NZ548358A (en) * 2001-02-09 2008-04-30 Genentech Inc Method of identifying agonists of insulin-like growth factor-1
US7071300B2 (en) * 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides

Also Published As

Publication number Publication date
HK1062923A1 (en) 2004-12-03
WO2003025121A2 (en) 2003-03-27
WO2003025121A3 (en) 2004-01-22
JP4344242B2 (ja) 2009-10-14
AU2002324672B2 (en) 2007-11-08
US6861406B2 (en) 2005-03-01
JP2005504801A (ja) 2005-02-17
EP1435986A2 (de) 2004-07-14
DE60224419D1 (de) 2008-02-14
CA2460719A1 (en) 2003-03-27
US20030059430A1 (en) 2003-03-27
EP1435986A4 (de) 2006-01-11
EP1435986B1 (de) 2008-01-02

Similar Documents

Publication Publication Date Title
ATE382364T1 (de) Von igf-bindungsprotein stammendes peptid
WO2004033481A3 (en) Igf-binding protein-derived peptide or small molecule
WO2004080405A3 (en) Igf-binding protein-derived peptide or small molecule
DE602004029812D1 (de) Fgf-5-bindende und geträgerte peptide
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
MXPA05010830A (es) Metodos de tratamiento que usan agentes de enlace especificos de angiopoyetina-2 humana.
DE60028970D1 (de) An her2 bindende peptidverbindungen
AR038568A1 (es) Anticuerpos anti-a beta y su uso
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
DK1673475T3 (da) Sammensætninger til diagnose og terapi af sygdomme, som er forbundet med aberrant ekspression af futriner (R-Spondiner) og/eller Wnt
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
ATE353222T1 (de) Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
WO2006052821A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
WO2004096856A3 (en) Secreted protein family
ATE344325T1 (de) Neisseria lactoferrin-bindendes protein
ATE482976T1 (de) Defensinproteine
EA200600956A1 (ru) Молекулы-антагонисты цитокинов
EA200700990A1 (ru) Новые пептиды, которые связывают рецептор эритропоэтина
SE0202608D0 (sv) New sequences
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
ATE456576T1 (de) Splice variante des menschlichen hypophysären wachstumshormons
WO2003025197A3 (en) Mutant sh3-binding protein compositions and methods

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties